vimarsana.com

Page 6 - Raymondw Cohen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Reviewing Axonics (NASDAQ:AXNX) and DexCom (NASDAQ:DXCM)

Axonics (NASDAQ:AXNX – Get Rating) and DexCom (NASDAQ:DXCM – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Axonics has a beta of 0.39, suggesting that its […]

Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

Axonics, Inc. , a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead. | June 18, 2023

Axonics, Inc (AXNX) Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

Axonics, Inc (AXNX) Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Axonics (NASDAQ:AXNX) versus DexCom (NASDAQ:DXCM) Critical Comparison

Axonics (NASDAQ:AXNX – Get Rating) and DexCom (NASDAQ:DXCM – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation. Analyst Recommendations This is a summary of recent ratings for Axonics and […]

Axonics (NASDAQ:AXNX) Price Target Cut to $73 00 by Analysts at Truist Financial

Axonics (NASDAQ:AXNX – Get Rating) had its price target decreased by Truist Financial from $82.00 to $73.00 in a report issued on Monday, The Fly reports. Truist Financial currently has a buy rating on the stock. Several other research firms have also weighed in on AXNX. Mizuho started coverage on shares of Axonics in a […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.